The significance of dense fine speckled pattern in antinuclear antibody-associated rheumatic disease and coexisting autoantibodies: A propensity score-matched cohort study.
ANA-associated rheumatic disease
anti-DFS70 antibody
anti-nuclear antibody
dense fine speckled
diagnosis
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
05
06
2023
received:
07
05
2023
accepted:
06
06
2023
medline:
5
9
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
To investigate the relationship between the prevalence of antinuclear antibody (ANA) -associated rheumatic diseases (AARD) and the presence of dense fine speckled (DFS) and homogeneous patterns in ANA tests. This retrospective study enrolled adult patients with either a DFS or homogeneous pattern in their ANA test. A mixed pattern was defined as the presence of more than one pattern reported in the test. The presence of anti-DFS70 antibodies and other common autoantibodies were detected using EUROLINE ANA Profile 23. A 1:2 propensity score matching was applied to control for demographic and other interfering factors. A total of 59 patients with a DFS pattern were enrolled and compared with a matched homogeneous group. The DFS group had a significantly lower prevalence of AARD (3.4% vs. 16.9%, p = .008) and the subgroup with anti-DFS70 antibodies showed an even lower prevalence (2% vs. 20%, p = .002). Among the 33 patients with monospecific anti-DFS70 antibodies, five had a mixed pattern, and all patients with common autoantibodies had an isolated DFS pattern. The findings of this study suggest that patients with a DFS pattern in their ANA test may have a lower prevalence of AARD compared with those with a homogeneous pattern. However, an isolated DFS pattern in ANA testing does not necessarily indicate the presence of monospecific anti-DFS70 antibodies or AARD. Confirmatory testing for the monospecific anti-DFS70 antibody is mandatory to exclude AARD.
Identifiants
pubmed: 37338084
doi: 10.1111/1756-185X.14789
doi:
Substances chimiques
Autoantibodies
0
Antibodies, Antinuclear
0
Adaptor Proteins, Signal Transducing
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1667-1675Subventions
Organisme : National Taiwan University Hospital Yunlin Branch
Informations de copyright
© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889.
Almaabdi K, Ahmad Z, Johnson SR. Advanced autoantibody testing in systemic sclerosis. Diagnostics (Basel). 2023;13(5):851.
Sulli A, Ruaro B, Smith V, et al. Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol. 2013;40(5):634-639.
Mahler M, Andrade LE, Casiano CA, Malyavantham K, Fritzler MJ. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol. 2019;15(3):241-250.
Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200.
Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587-592.
Ochs RL, Mura Y, Si Y, Ge H, Chan EKL, Mtan E. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 II):1211-1220.
Watanabe A, Kodera M, Sugiura K, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900.
Mahler M, Parker T, Peebles CL, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-2110.
Conrad K, Rober N, Rudolph S, Mahler M. DFS70 antibodies-biomarker for exclusion of ANA associated rheumatic diseases. Laboratoriumsmedizin-journal of. Lab Med. 2014;38(6):299-307.
Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS ONE. 2014;9(4):e93812.
Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 2008;17(3):171-176.
Infantino M, Pregnolato F, Bentow C, et al. Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clin Chem Lab Med. 2019;57:1764-1769.
Vishnu BS, Rajesh S. Clinical characteristcs of patents with isolated AntDFS 70 antbody positvity. Indian J Rheumatol. 2019;14(6):S157.
Bonroy C, Schouwers S, Berth M, et al. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med. 2018;56(7):1090-1099.
Hayashi N, Uto K, Imanishi A, Sugiyama D, Morinobu A, Saegusa J. Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. Medicine (Baltimore). 2021;100(9):e24556.
Shovman O, Gilburd B, Chayat C, et al. Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol. 2018;36(1):121-126.
Tan TC, Ng CYL, Leong KP. Clinical utility of anti-DFS70 for identifying antinuclear antibody-positive patients without systemic autoimmune rheumatic disease. Singapore Med J. 2022;63(3):147-151.
Kiefer D, von Brunn M, Baraliakos X, Andreica I, Braun J. Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases. Z Rheumatol. 2020;79(8):749-754.
Zhang K, Su Z, Hu J, Huang Z, Hu C, Yang B. Dense fine speckled immunofluorescence pattern in a Chinese population: prevalence and clinical association. J Clin Lab Anal. 2022;36(2):e24173.
Mockenhaupt LM, Dolscheid-Pommerich R, Stoffel-Wagner B, Behning C, Brossart P, Schäfer VS. Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases. Semin Arthritis Rheum. 2022;52:151936.
Karahan S, Emre Ş, Hörmet-Öz HT. Anti-dense fine speckled (DFS) antibody: its staining pattern in indirect immunofluorescence and its clinical relevance. Rom J Intern Med. 2022;60(1):66-76.
Choi MY, Clarke AE, St Pierre Y, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051-1059.
Dai Y, Li E, Chen D, et al. Anti-DFS70 antibodies in systemic lupus erythematosus: prevalence in a large Chinese cohort and an unexpected association with anti-dsDNA antibodies by a long-term follow-up. Front Immunol. 2022;13:913714.
Freudenhammer M, Salzer U, Heselich A, Hufnagel M, Janda A. Low prevalence of anti-DFS70 antibodies in children with ANA-associated autoimmune disease. Front Pediatr. 2022;10:839928.
Cheng CF, Shih MC, Lan TY, Li KJ. Anti-DFS70 antibodies for differentiating systemic autoimmune rheumatic disease in patients with positive ANA tests: a systematic review and meta-analysis. Diagnostics (Basel). 2021;11(9):1592.
Moroni L, Restovic G, Cervera R, et al. Economic analysis of the use of anti-DFS70 antibody test in patients with undifferentiated systemic autoimmune disease symptoms. J Rheumatol. 2020;47(8):1275-1284.
Miyara M, Albesa R, Charuel JL, et al. Clinical phenotypes of patients with anti-Dfs70/Ledgf antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:1-8.
Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615-1623.
Voskuhl R. Sex differences in autoimmune diseases. Biol Sex Differ. 2011;2(1):1.
Albesa R, Sachs U, Infantino M, et al. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors. Clin Chem Lab Med. 2019;57(7):999-1005.
Carbone T, Pafundi V, Tramontano G, et al. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Sci Rep. 2019;9(1):2177.
Vulsteke JB, Van Hoovels L, Willems P, et al. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis. 2019;80:e128.
Lundgren MC, Sapkota S, Peterson DJ, Crosson JT. The antinuclear antibody dense fine speckled pattern and possible clinical associations: an indication of a proinflammatory microenvironment. J Immunol Methods. 2021;488:112904.
Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1-28.
Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Autoimmun Highlights. 2016;7(1):8.
Mahler M, Meroni PL, Andrade LE, et al. Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev. 2016;15(2):198-201.
Gundín S, Irure-Ventura J, Asensio E, et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Autoimmun Highlights. 2016;7(1):10.
Basu A, Woods-Burnham L, Ortiz G, et al. Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2. Clin Immunol. 2015;161(2):241-250.
Sanchez-Hernandez ES, Ortiz-Hernandez GL, Ochoa PT, et al. The nuclear dense fine speckled (DFS) immunofluorescence pattern: not all roads lead to DFS70/LEDGFp75. Diagnostics (Basel). 2023;13(2):222.
Zheng B, Wang Z, Mora RA, et al. Anti-DFS70 antibodies among patient and healthy population cohorts in China: results from a multicenter training program showing spontaneous abortion and pediatric systemic autoimmune rheumatic diseases are common in anti-DFS70 positive patients. Front Immunol. 2020;11:562138.
Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol. 2002;127(1):172-175.
Aragón CC, Posso-Osorio I, Puerta G, et al. Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases. Clin Rheumatol. 2020;39(7):2163-2169.
Romero-Sánchez C, Calixto OJ, Romero-Alvarez V, et al. Analysis of Ana/Dfs70 pattern in a large cohort of autoimmune/autoinflammatory diseases compared with first degree relatives and healthy controls evaluated from Colombia. Diagnostics (Basel). 2022;12(9):2181.
Cheng CF, Lan TY, Shih MC, Li KJ. Monospecific anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fine speckled pattern - a systematic review and meta-analysis of diagnostic test accuracy. Autoimmun Rev. 2020;19(10):102637.
Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: Not an easy task! Comment on the article by Mariz Villalta D. Arthritis Rheum. 2011;63(12):4036-4037.
Bizzaro N, Tonutti E, Tampoia M, et al. Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta. 2015;451:271-277.
Türkoǧlu G, Berkem R, Karakoç AE. Investigation of the diagnostic value of anti-dense fine speckled 70/lens epithelium derived growth factor p75 autoantibody for autoimmune diseases. Mikrobiyoloji Bulteni. 2018;52(4):413-424.